WallStreetZenWallStreetZen

NASDAQ: TRAW
Traws Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TRAW

Based on 1 analyst offering 12 month price targets for Traws Pharma Inc

Min Forecast
$8.00+266.97%
Avg Forecast
$8.00+266.97%
Max Forecast
$8.00+266.97%

Should I buy or sell TRAW stock?

Based on 1 analyst offering ratings for Traws Pharma Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TRAW stock forecasts and price targets.

TRAW stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-03

1 of 1

Forecast return on equity

Is TRAW forecast to generate an efficient return?

Company
N/A
Industry
67.13%
Market
179.62%

Forecast return on assets

Is TRAW forecast to generate an efficient return on assets?

Company
N/A
Industry
31.85%

TRAW earnings per share forecast

What is TRAW's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$3.38-103.47%
Avg 2 year Forecast
-$3.06-103.14%

TRAW revenue forecast

What is TRAW's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$13.4M+369.5%
Avg 3 year Forecast
$58.2M+1,946.45%
TRAW's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TRAW revenue growth forecast

How is TRAW forecast to perform vs Biotechnology companies and vs the US market?

Company
162.72%
Industry
35.72%
Market
13.42%
TRAW's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TRAW's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TRAW vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRAW$2.18$8.00+266.97%Buy
ALLR$1.10$9.50+763.64%Buy
FBLG$0.26$5.50+2,048.44%Strong Buy
INAB$1.72$6.00+248.84%Buy
LEXX$0.73$1.50+106.90%Buy
View Top Biotech Stocks

Traws Pharma Stock Forecast FAQ

Is Traws Pharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: TRAW) stock is to Buy TRAW stock.

Out of 1 analyst, 0 (0%) are recommending TRAW as a Strong Buy, 1 (100%) are recommending TRAW as a Buy, 0 (0%) are recommending TRAW as a Hold, 0 (0%) are recommending TRAW as a Sell, and 0 (0%) are recommending TRAW as a Strong Sell.

If you're new to stock investing, here's how to buy Traws Pharma stock.

What is TRAW's earnings growth forecast for 2026-2027?

(NASDAQ: TRAW) Traws Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.93%.

Traws Pharma's earnings in 2026 is $93,350,000.On average, 4 Wall Street analysts forecast TRAW's earnings for 2026 to be -$26,990,751, with the lowest TRAW earnings forecast at -$33,853,308, and the highest TRAW earnings forecast at -$19,297,944.

In 2027, TRAW is forecast to generate -$24,452,053 in earnings, with the lowest earnings forecast at -$36,884,244 and the highest earnings forecast at -$10,823,629.

What is TRAW's revenue growth forecast for 2026-2028?

(NASDAQ: TRAW) Traws Pharma's forecast annual revenue growth rate of 162.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.42%.

Traws Pharma's revenue in 2026 is $2,846,000.On average, 4 Wall Street analysts forecast TRAW's revenue for 2026 to be $0, with the lowest TRAW revenue forecast at $0, and the highest TRAW revenue forecast at $0. On average, 4 Wall Street analysts forecast TRAW's revenue for 2027 to be $106,773,965, with the lowest TRAW revenue forecast at $0, and the highest TRAW revenue forecast at $219,828,751.

In 2028, TRAW is forecast to generate $465,404,076 in revenue, with the lowest revenue forecast at $447,152,936 and the highest revenue forecast at $479,092,431.

What is TRAW's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TRAW) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.85%.

What is TRAW's Price Target?

According to 1 Wall Street analyst that have issued a 1 year TRAW price target, the average TRAW price target is $8.00, with the highest TRAW stock price forecast at $8.00 and the lowest TRAW stock price forecast at $8.00.

The Wall Street analyst predicted that Traws Pharma's share price could reach $8.00 by Dec 3, 2026. The average Traws Pharma stock price prediction forecasts a potential upside of 266.97% from the current TRAW share price of $2.18.

What is TRAW's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: TRAW) Traws Pharma's current Earnings Per Share (EPS) is $97.38. On average, analysts forecast that TRAW's EPS will be -$3.38 for 2026, with the lowest EPS forecast at -$4.24, and the highest EPS forecast at -$2.42. In 2027, TRAW's EPS is forecast to hit -$3.06 (min: -$4.62, max: -$1.35).

What is TRAW's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TRAW) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.